Artemisia annua L. is used throughout Asia and Africa as tea and press juice to treat malaria
and related symptomes (fever, chills). Its active ingredient, artemisinin (ARS), has been …

Artemisinin‐based combination therapy (ACT) has been adopted as a strategy to mitigate
multidrug resistance to antimalarial monotherapies. ACT combines the rapid and effective …

Malaria contributes to the most widespread infectious diseases worldwide. Even though
current drugs are commercially available, the ever-increasing drug resistance problem by …

Background Artemisinin-based combination therapy (ACT) is the first-line anti-malarial
treatment of uncomplicated malaria in most malaria endemic countries, including Tanzania …

Background Malaria is a major cause of morbidity and mortality in pediatrics in malaria
endemic areas. Artemisinin-based combination therapies (ACTs) are the drugs of choice for …

Abstract Background The World Health Organization recommends regular therapeutic
efficacy studies (TES) to monitor the performance of first and second-line anti-malarials. In …

Colorectal cancer (CRC) is a leading cause of cancer death in the United States. Artemisinin
derivatives, including the dihydroartemisinin (DHA) monomers, are widely used as clinical …

Abstract Background Since 2005, the Togo National Malaria Control Programme has
recommended two different formulations of artemisinin-based combination therapy (ACT) …

Background The emergence of artemisinin resistance in Southeast Asia and Plasmodium
falciparum kelch13 propeller gene mutations in sub-Saharan African pose the greatest …

Abstract Background In 2004, Ethiopia adopted artemether-lumefantrine (AL, Coartem®) as
first-line treatment for the management of uncomplicated Plasmodium falciparum malaria …